320 related articles for article (PubMed ID: 36370049)
21. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
[TBL] [Abstract][Full Text] [Related]
23. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
24. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.
Terada K; Yamaguchi H; Ueki T; Usuki K; Kobayashi Y; Tajika K; Gomi S; Kurosawa S; Saito R; Furuta Y; Miyadera K; Tokura T; Marumo A; Omori I; Sakaguchi M; Fujiwara Y; Yui S; Ryotokuji T; Arai K; Kitano T; Wakita S; Fukuda T; Inokuchi K
Genes Chromosomes Cancer; 2018 Aug; 57(8):401-408. PubMed ID: 29663558
[TBL] [Abstract][Full Text] [Related]
27. NOTCH-1 Gene Mutations Influence Survival in Acute Myeloid Leukemia Patients.
Aref S; Rizk R; El Agder M; Fakhry W; El Zafarany M; Sabry M
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1987-1992. PubMed ID: 32711424
[TBL] [Abstract][Full Text] [Related]
28. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
29. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
31. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
32. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
33. Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Int J Cancer; 2023 Mar; 152(5):977-985. PubMed ID: 36251447
[TBL] [Abstract][Full Text] [Related]
34. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
35. Cytogenetic abnormalities in
Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
[No Abstract] [Full Text] [Related]
36. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
37. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
38. Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia.
Zhang Y; Wu Q; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Jiang Y; Ye J; Jiang X
BMC Cancer; 2023 Oct; 23(1):1030. PubMed ID: 37875840
[TBL] [Abstract][Full Text] [Related]
39. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
[TBL] [Abstract][Full Text] [Related]
40. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
Ambinder A; Smith M; Tsai HL; Varadhan R; DeZern A; Dalton W; Gocke C; Webster J; Gondek L; Gojo I; Ali SA; Huff CA; Swinnen L; Wagner-Johnston N; Showel M; Prince G; Borrello I; Bolaños-Meade J; Luznik L; Jain T; Imus P; Fuchs E; Ambinder R; Gladstone DE; Levis M; Jones R; Ghiaur G; Smith BD
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):260-269. PubMed ID: 34750086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
